| [1] |
HeroldC I, Blackwell K L. The impact of adjuvant endocrine therapy on reducing the risk of distant metastases in hormoneresponsive breast cancer. Breast,2008,17:S15 -S24.
|
| [2] |
Doisneau Sixou S F,Serqio C M,Carroll J S,et al.Estrogen and antiestrogen regulation of cell cycle progression in breast cancer cells.Endocr Relat Cancer,2003,10:179 -186.
|
| [3] |
Waeber M,Castiqlione Gertsch M,Dietrich D, et al. Adjuvant therapy after excision and radiation of isolated postmastectomy locoregional breast cancer recurrence:definitive results of a phase III randomized trial(SAKK23/82)comparing tamoxifen with observation.Ann Oncol,2003,14:1215 -1221.
|
| [4] |
Fisher B,Dignam J,Bryant J, et al.Five versus more than five years of tamoxifen for lymph node-negative breast cancer:updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 Randomized Trial. J Natl Cancer Inst,2001,93:684 -90.
|
| [5] |
张惠,徐玉秀,陈星薇,等.77 例服用他莫昔芬的乳腺癌患者脂肪肝的超声观察.北京医学,1999,21:51 -52.
|
| [6] |
Mouridsen H,Gershanovich M. The role of aromatase inhibitors inthe treatment of metastatic breast cancer. Semin Oncol,2003,30 :33 -45.
|
| [7] |
Del Mastro L,Clavarezza M,Venturini M. Reducing the risk of distant metastases in breast cancer patients: role of aromatase inhibitors,2007,33:681 -687.
|
| [8] |
Ficker J. Letrozole better than tamoxifen in postmenopausal women. Lancet Oncol,2005,6:137 -138.
|
| [9] |
Pennery E. The role of endocrine therapies in reducing risk of recurrence in postmenopausal women with hormone receptorpositive breast cancer. Eur J Oncol Nurs, 2008,[Epub ahead of print ].
|
| [10] |
Crivellari D, Sun Z, Coates A S, et al. Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial. Clin Oncol,2008,26:1972 -1979.
|
| [11] |
Mouridsen H,Gershanovich M,Sun Y, et al.Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer:results of a phase III study of the Internation Letrozole Breast Cancer Group. J Clin Oncol,2001,19:2596-2606.
|
| [12] |
Goss P E , Ingle J N , Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Enql J Med,2003,349:1793 -1802.
|
| [13] |
Buzdar A U. Advances in endocrine treatments for postmenopausal women with metastatic and early breast cancer.Oncologist,2003,8:335-341.
|
| [14] |
Aapro M S , Forbes J F. Three years'follow up from the ATAC trial is sufficient to change clinical practice : a debate. Breast Cancer Res Treat,2003,80:S3 -S11.
|
| [15] |
Buzdar A. Anastrozole as adjuvant therapy for early-stage breast cancer : implications of the ATAC trial. Clin Breast Cancer,2003,4:S42 -48.
|
| [16] |
Baum M,Budzar A U,Cuzick J,et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer :first results of the ATAC randomised trial. Lancet, 2002,359:2131 -2139.
|
| [17] |
Jakesz R, Jonat W, Gnant M, et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years'adjuvant tamoxifen:combined results of ABCSG trial 8 and ARNO 95 trial.Lancet,2005,366:455 -462.
|
| [18] |
Kaufmann M, Jonat W, Hilfrich J,et al. Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 Study. Clin Oncol,2007,25:2664 -2670.
|
| [19] |
Paridaens R, Dirix L, Beex L, et al. Promising results with exemestane in the first-line treatment of metastatic breast cancer: a randomized phase II EORTC trial with a tamoxifen control.Clin Breast Cancer,2000,1:S19 -S21.
|
| [20] |
Iddon J, Bundred N J. To switch or not to switch: should the updated Intergroup Exemestane Study alter our decision? Expert Rev Anticancer Ther,2008,8:9 -13.
|
| [21] |
Coombes R C, Hall E, Gibson L J, et al.A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med,2004,350:1081 -1092.
|
| [22] |
Robertson J F, Blamey R W. The use of gonadotrophinreleasing hormone(GnRH) agonists in early and advanced breast cancer in pre-and perimenopausal women.Eur J Cancer,2003,39:861 -869.
|
| [23] |
Klijn J G, Blamey R W, Boccardo F, et al. Combined tamoxifen and luteinizing hormone-releasing hormone(LHRH)agonist versus LHRH agonist alone in premenopausal advanced breast cancer:a meta-analysis of four randomized trial. Clin Oncol,2001,19:343 -353.
|
| [24] |
Jakesz R, Hausmaninger H, Kubista E, et al. Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide,methotrexate,and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer-Austrian Breast and Colorectal Cancer Study Group Trial 5.Clin Oncol,2002,20:4621-4627.
|
| [25] |
Davidson N E,O'Neill A M,Vukov A M, et al. Chemoendocrine therapy for premenopausal women with axillary lymph nodepositive,steroid hormone receptor-positive breast cancer:results from INT 0101(E5188).Clin Oncol,2005,23:5973-5982.
|